Related Experiment Videos
Targeting leukocyte integrins in human diseases
Karyn Yonekawa1, John M Harlan
1Division of Nephrology, Department of Pediatrics, University of Washington, Seattle, WA, USA.
Journal of Leukocyte Biology
|November 19, 2004
Summary
Leukocyte integrins are crucial in inflammation and disease. Targeting these adhesion molecules with antagonists shows promise for treating inflammatory conditions like psoriasis and multiple sclerosis.
Area of Science:
- Immunology
- Cell Biology
- Pharmacology
Background:
- Integrins are key adhesion and signaling molecules.
- Leukocyte integrins play a critical role in immune-mediated and inflammatory processes.
- These molecules are implicated in diverse clinical disorders, including asthma and atherosclerosis.
Purpose of the Study:
- To review the role of leukocyte integrins in inflammation.
- To discuss approaches for targeting leukocyte integrins and their ligands.
- To summarize the outcomes of clinical trials involving integrin antagonists.
Main Methods:
- Review of scientific literature on integrin function and therapeutic targeting.
- Analysis of preclinical models and clinical trial data for integrin antagonists.
- Discussion of the mechanisms of action for antiadhesion therapies.
Main Results:
- Integrin antagonists have shown efficacy in preclinical models of inflammatory diseases.
- Clinical trial success has been variable, with some failures in ischemia-reperfusion and transplantation.
- Recent successes in psoriasis, inflammatory bowel disease, and multiple sclerosis highlight therapeutic potential.
Conclusions:
- Leukocyte integrins are validated therapeutic targets for inflammatory diseases.
- Targeting leukocyte integrin function offers a promising antiadhesion therapy strategy.
- Further research and development are needed to optimize integrin antagonist therapies for clinical use.